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ABSTRACT
Introduction Ambient ozone exposure may be adverse 
to health. Since the reported associations between ozone 
and health effects are heterogeneous and the underlying 
pathways are indistinct, the overall relationship remains 
unclear. Only a few overall syntheses of the evidence 
regarding ozone and health effects are available to date.
Methods and analysis We plan to summarise the current 
evidence on ozone- related health effects systematically. 
First, to identify the possible associations between 
ambient ozone exposure and health outcomes, we will 
conduct an umbrella review. PubMed, Web of Science and 
grey literature will be searched for systematic reviews 
on exposure to ambient ozone and any possible health 
endpoints published before 31 May 2019. Data selection 
and extraction will be carried out by one reviewer, and a 
second reviewer will check the agreement of a sample 
of the studies. The methodological quality of the eligible 
systematic reviews and level of evidence regarding 
ozone and every specific health effect will be evaluated. 
Second, for each of the identified effects with a high 
level of evidence, comprehensive information retrievals 
will be conducted, considering both epidemiological 
and experimental studies. The study selection and data 
mapping will be carried out by one reviewer and checked 
by the second reviewer. We will summarise the information 
of the filtered epidemiological and experimental studies to 
conduct several systematic maps presenting the currently 
available evidence for the specific health effect. Because 
the association between ozone exposure and chronic 
obstructive pulmonary disease (COPD) is relatively well 
investigated, we will at least conduct one systematic map 
of ozone and COPD.
Ethics and dissemination No ethical approval is required 
for this study. The completed umbrella review and 
systematic maps will be considered for publication and 
presentation. We will additionally upload the relevant data 
to publicly accessible online databases.
PROSPERO registration number CRD42019123064.
INTRODUCTION
Ambient air pollution has been considered a 
leading cause of the global burden of disease 
(GBD).1 According to the GBD study, air 
pollution was estimated to account for 4.9 
million deaths (95% uncertainty interval 
(UI) 4.4–5.49 million) and 147.0 million 
(132.0–162.0 million) disability- adjusted life 
years (DALYs) in 2017.2
Although the majority of the air pollution- 
related burden is attributed to particulate 
matter (PM) in the GBD studies,2–4 the 
burden from ambient ozone pollution is 
also alarming. In 2017, ambient ozone expo-
sure caused 472 000 (95% UI 177 000–768 
000) deaths and a loss of 7.4 million (2.7–
12.0 million) DALYs.2 In addition, consid-
ering climate change, global warming and 
increased emissions of ozone precursors, 
the long- term ambient ozone is expected 
to increase in concentration.5 Thus, ozone- 
related mortality might grow in the future.6
The association between ozone and chronic 
obstructive pulmonary disease (COPD) is 
regarded to be in line with the basis of evidence 
rules by the GBD study group,2 and COPD 
is, thus, the only one ozone- related health 
outcome included in the GBD study 2017.2 
A lack of evidence for other effects is largely 
Strengths and limitations of this study
 ► To the best of our knowledge, this protocol is the 
first one for an umbrella review or a systematic map 
focusing on ozone exposure and health outcomes.
 ► The umbrella review will provide a comprehensive 
outline of the currently available systematic reviews 
on ambient ozone exposure and health outcomes, 
and an epidemiological evidence reservoir accessi-
ble to the public.
 ► The systematic map of a specific ozone- related 
health effect would be the first of this kind to syn-
thesise evidence from both epidemiological and ex-
perimental studies.
 ► Since the umbrella review will include only pub-
lished systematic reviews, the quality of evidence 
will, thus, depend on the included reviews, and 
some latest original high- quality studies may be 
neglected.
 ► Publication bias and quality of the original studies 
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explained by ozone is under investigated compared with 
PM, and because based on the hierarchy of evidence,7 the 
conducted epidemiological observational studies are not 
considered as a high quality.
Regarding the evidence, a systematic review is a standard 
method for summarising and analysing available evidence 
on health issues. Systematic reviews are regarded to be of 
high evidence hierarchy and of low risk of bias.7 Currently, 
as systematic reviews have synthesised a growing number 
of original studies, more evidence is accumulating. From 
these reviews, we can find out ozone exposure linked to 
different kinds of health effects, not only to the respi-
ratory system but also to the cardio- cerebrovascular,8 9 
central nervous system10 11 or mental health.12 13 Conse-
quently, the possibility of tracing evidence up to date has 
been overwhelmed by the rapidly increased number of 
systematic reviews.14
Remarkably, an umbrella review, systematically 
reviewing previously published systematic reviews, could 
generate a higher level of the hierarchical evidence7 and 
has attracted increasing research attention. This trend 
can be identified by the number of newly published 
umbrella reviews15 16 and protocols17–19 on various 
topics. An umbrella review would be a feasible way to 
outline the associations between ozone exposure and 
health effects.
On the other hand, biological mechanisms that 
possibly lie behind the associations reported by epidemi-
ological studies are relatively unclear—although expo-
sure to ozone has been postulated to be associated with 
adverse health effects via oxidative stress and inflamma-
tory response.20 21 More and more efforts are trying to 
bridge the gap between epidemiological associations 
and biological relevance, yet they are largely restricted to 
descriptive discussion of the results from relevant exper-
imental studies22 23 or narrative review of studies with a 
similar setting.24 There still is an absence of any systematic 
syntheses of evidence on a specific ozone- related health 
effect.
Therefore, a systematic map25 26 or a systematic evidence 
map,27 which uses systematic search and strategical selec-
tion but seeks no evidence synthesis, is an appropriate 
emerging method to comprehensively summarise and 
catalogue the ozone- related broad and miscellaneous 
evidence from original experimental studies, as well as 
original epidemiological studies.
On this background, we aim to perform an umbrella 
review on ambient ozone exposure and health effects 
by systematically reviewing existing systematic reviews. 
We will additionally supplement those significant ozone- 
effect pairs filtered from the umbrella review with original 
epidemiological and experimental evidence, to provide a 
more comprehensive picture on ozone and health. This 
study will (1) identify exposure- related health effects 
of ambient ozone by an umbrella review and (2) inte-
grate current available epidemiological studies, and 
cross- reference the effects with experimental studies, by 
conducting systematic maps.
METHODS AND ANALYSIS
This project has been registered on the International 
Prospective Register of Systematic Reviews (https://
www. crd. york. ac. uk/ prospero/) on 24 April 2019.28 The 
present protocol was developed and modified in accor-
dance with the Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols (PRISMA- P) 2015 
checklist29 and the guidance on systematic maps published 
by the Collaboration for Environmental Evidence.30 31
Patient and public involvement
This study will have no patient or public involvement and 
will collect no primary data.
Study design
The project will be divided into two processes. The first 
process will be an umbrella review. In other words, a 
systematic review to identify the published systematic 
reviews on the association between ambient ozone expo-
sure and any health endpoints. We will further grade the 
evidence of ozone- effect pairs based on parameters from 
the systematic reviews with meta- analysis.32 33 The second 
process will be the development of systematic maps for 
the specific health effects with high evidence levels iden-
tified by the umbrella review. For example, if COPD were 
to be identified as an ozone- related health effect with a 
high evidence level, we would conduct a systematic map 
of ozone exposure and COPD. Every systematic map will 
contain all of the published original epidemiological 
studies, as well as the currently available experimental 
studies of the specific health effect.
Umbrella review
In our registered protocol,28 we specified that the first 
process will contain three search paths: a systematic review 
of systematic reviews, of the burden of disease studies 
and of relevant study reports. The current protocol has 
been renamed ‘systematic review of systematic reviews’ to 
‘umbrella review’, and contains no systematic review of 
the burden of disease studies. The detailed table of PRIS-
MA- P is listed in the Supplementary (online supplemen-
tary table S1).
The process of the umbrella review will be guided by 
the PRISMA guideline.34 Given no agreed method for 
conducting an umbrella review,7 our methodology will 
be performed in accordance with previously published 
umbrella review on risk factors (eg, dietary factor, life-




The general human population will be considered, 
regardless of age, sex, race, region, as well as health states.
Types of exposure (intervention)
The exposure is ambient ozone. Indoor and occupational 
exposure will not be considered.
 on S
eptem









pen: first published as 10.1136/bm





3Zhao T, et al. BMJ Open 2020;10:e034854. doi:10.1136/bmjopen-2019-034854
Open access
Types of comparator
Comparisons are varied across studies. Generally, the 
comparison is between the participants or periods with 
lower levels of ambient ozone exposure and the more 
highly exposed populations or periods.
Types of outcome
Any possible health effects, such as symptoms, condi-
tions, diseases, morbidity, mortality, considering both 
the long- term or chronic effects and the short- term or 
acute effects, will be our outcomes of interest. Addition-
ally, several possible indirect indicators, such as restricted 
activity days, days with symptoms or hospital admissions, 
will be involved where applicable.
Inclusion criteria
We will include the systematic reviews that investigated 
ambient ozone exposure and health effects, published 
before 31 May 2019, written in English or German.
Exclusion criteria
We will not include articles, abstracts, dissertations or 
letters. Cell or animal studies and botanical studies will 
be excluded. The papers about indoor or occupational 
ozone exposure and clinical studies on ozone therapy will 
not be considered.
Information source and search strategy
Databases to be searched will include PubMed and Web 
of Science. Combinations of both free terms and Medical 
Subject Headings (MeSH) connected with ‘ozone’ and 
‘systematic review’ or ‘meta- analysis’ will be used for 
search (online supplementary table S2).
Reference lists of included studies will be searched 
manually for potentially relevant papers. Additionally, 
grey literature, such as reports from relevant institutes, 
will be searched on their websites. A list of relevant insti-
tutes (online supplementary table S3) is adopted and 
updated from a previous project.38
Study management and selection
The assessed studies will be imported to EndNote V.X8 
software. After deduplication, the selection process 
contains two stages: an initial screening of the titles 
and abstracts based on the aforementioned criteria and 
followed by a second screening of the full texts of the 
papers filtered by the initial screening. The entire process 
will be illustrated by a PRISMA flow chart.
One member of the reviewer team (TZ) will inde-
pendently conduct the study selection. A second reviewer 
(NSM) will check the agreement of a randomly selected 
sample of the studies (at least 10%). The strength of the 
agreement will be calculated by the Kappa score. Further 
disagreements will be determined through consensus by 
a third member (JH).
Data extraction
A predesigned Microsoft Excel table39 will be revised and 
used for extracting data from the selected studies (online 
supplementary file 2). The extracted information will 
include the first author, year of publication, journal, type 
of study (systematic review with or without meta- analysis), 
search results (name of database, date of search, number 
of hits), key information of included studies (the overall 
population–exposure–comparator–outcome (PECO) or 
population–intervention–comparator–outcome (PICO) 
statement) and the summarised ozone- related results 
of the included studies, as well as the method of quality 
assessment and/or risk of bias used by the studies. When 
the data of interest are incomplete, the corresponding 
author will be contacted for acquiring additional infor-
mation. Furthermore, for the involved systematic reviews 
with meta- analysis, data on the total number of cases, 
effect estimates (eg, OR or risk ratio), confidence inter-
val(CI), p value, as well as results about heterogeneity (eg, 
the I2 statistic, the Q value and the associated p value) 
and results on publication bias (eg, Egger test) will be 
recorded. One member of the reviewer team (TZ) will 
extract the information. The second reviewer (NSM) will 
check the agreement of a randomly selected sample of 
the studies (more than 10%).
Study assessment
We will adopt ‘a measurement tool to assess systematic 
reviews 2’ (AMSTAR2) criteria40 to evaluate the meth-
odological quality of included systematic reviews and 
meta- analyses. The AMSTAR2 contains 16 items in total, 
and 7 out of them are considered as critical domains. 
The assessment by AMSTAR2 generates no score but an 
overall rating of the review, that is, high, moderate, criti-
cally low and low. A detailed description of AMSTAR2 can 
be accessed elsewhere.40
Data analysis
For the included systematic reviews, we will qualitatively 
describe their main results in a summary table. The table 
will contain the first author, year of publication, key infor-
mation of included studies (the overall PECO or PICO 
statement), the summarised ozone- related results and the 
results of AMSTAR2. Moreover, information on the total 
number of cases, effect estimates, CI, p value, heteroge-
neity and publication bias will be listed for the systematic 
reviews with meta- analysis.
Apart from the descriptive information, quantity anal-
ysis will be conducted for meta- analysis where appli-
cable. In case two or more studies present overlapping 
datasets of original studies on the same health effect, 
we will retain the study with the largest datasets.32 A 
random effect p value of a meta- analysis will be mainly 
adopted. A prediction interval41 indicating the hetero-
geneity between studies and estimating the uncertainty 
of effect estimate in a future new study will be calcu-
lated based on the extracted data of the identified 
meta- analysis.
A standard formula for a prediction interval based on k 
studies can be obtained as
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Where τ̂2 is a point estimate of the heterogeneity vari-




%  percentile of the t- distribu-
tion with k−2 degrees of freedom.41
In order to compare the different effect estimates 
across studies, we will recalculate the various effect esti-
mates into ORs.33 39
Finally, a classification of levels of evidence (table 1) 
summarised by the previously published umbrella 
reviews35–37 will be used and updated to grade the ozone–
health effect pairs. The health effects classified to have 
classes I–III evidence will be considered to have a high 
level of evidence.
Synthesis of results
The results of this umbrella review will include the flow 
chart of the literature search process, the aforemen-
tioned summary table, and a synthesis table for meta- 
analysis containing the results of the quantitative analysis. 
We anticipate discussing the overall descriptive results of 
the assessed systematic reviews, and the classification of 
levels of evidence regarding ozone–health effect pairs.
Systematic map
Based on the results of the umbrella review, the second 
process of the project will focus on the identified ozone- 
related health outcomes with high evidence levels (class 
I, II or III). However, given COPD is widely investigated 
and included already in the GBD study,2 we will conduct 
a systematic map of ozone and COPD regardless of the 
confidence level stemmed from the umbrella review.
Unlike the registered protocol,28 we revised the second 
process of this project. The updated systematic map 
will cover both the published epidemiological studies 
and experimental studies. The current PRISMA- P table 
in Supplementary (online supplementary table S4) is 
adopted from the RepOrting standards for Systematic 
Evidence Syntheses42 and the journal Environment Interna-
tional .31
A revised PRISMA reporting guidelines and checklist43 
will be used to guide the process of systematic maps. 
The planned systematic maps will mirror the guidelines 
established by the National Toxicology Program/Office 
of Health Assessment, Development and Translation 
(OHAT)44 as well.
Eligibility criteria
Types of PECO or PICO
A general PECO or PICO statement for systematic maps 
is listed in table 2.
Inclusion and exclusion criteria
The studies included in systematic maps should contain 
original research investigating ozone exposure and the 
health effects with high levels of evidence identified by 
the umbrella review. The epidemiological, experimental 
or toxicological studies in line with the PECO or PICO 
statement will be included. Articles on clinical ozone 
therapy and botanical studies will be excluded. Reviews, 
letters or conference abstracts will not be involved in 
systematic maps.
We will have no requirements on publication dates 
for a systematic map. Articles published in the English 
language will be focused on.
Information source and search strategy
The search will be conducted in PubMed and Web 
of Science, using both free terms and MeSH terms for 
ozone and the identified health effects. Reference lists of 
included articles and systematic reviews on the same topic 
identified by the umbrella review will be searched manu-
ally for potentially relevant papers.
Table 1 Levels of evidence
Evidence Class Requirement
Convincing Class I Number of cases >1000, meta- 
analysis p value <10−6, between 
study heterogeneity I2 <50% and 
95% prediction interval excluding 




Class II Number of cases >1000, meta- 
analysis p value <10−6, the largest 
study with a statistically significant 
effect and class I criteria not meet
Suggestive Class III Number of cases> 1000, meta- 
analysis p value <10−3 and class I or 
II criteria not meet
Weak Class IV Meta- analysis p value <0.05 and 
classes I–III criteria not meet
Non- 
significant
Null meta- analysis p value> 0.05
Table 2 PECO or PICO statement for systematic maps
Element Description
Populations Any human (epidemiological studies or human 
exposure studies), or animal, or ex vivo/in vitro 
studies using organs, tissues, cells, or cellular 
components, for example, cell- free receptor 




Ambient ozone exposure in epidemiological studies 
or ozone exposure in experimental or toxicological 
settings
Comparator Study populations or periods (person- time) 
exposed to a lower level of ozone (epidemiological 
studies) or the control groups (experimental or 
toxicological studies) than the more highly exposed 
subjects, periods (person- time) or groups
Outcomes COPD and any health effects with high evidence 
levels identified in the umbrella review
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Since the results of the umbrella review will provide 
outcomes of systematic maps, we currently cannot report 
the entire search strategy. However, regarding the case of 
COPD, a general strategy would be “(ozone OR O3) AND 
(“chronic obstructive pulmonary disease” OR COPD)”.
Study management and selection
One member of the review team (TZ) will conduct the 
study selection. The second reviewer (NSM) will check 
the agreement of a sample of the studies (more than 
10%). A third member (JH) would be involved in the case 
of disagreement. The assessed studies will be imported 
to EndNote V.X8 software. After deduplication, we will 
upload the data to Health Assessment Workspace Collab-
orative (HAWC, https:// hawcproject. org/) for manage-
ment and screening. HAWC is an online open- source 
platform providing a transparent method for study selec-
tion, data extraction, data assessment, evidence synthesis 
and data visualisation.45 46
Data coding strategy
After the full- text screening, a coding tool will be designed 
and updated to extract and record data from the included 
studies. Based on the OHAT protocol,44 45 extracted 
information could involve: study identification infor-
mation (first author, year of publication), type of study 
(epidemiological or animal, or ex vivo/in vitro study), 
key information of included studies (the overall PECO 
or PICO statement), as well as the summarised conclu-
sions of a study. Additional information about conflict of 
interest, funding statements and acknowledgements will 
be extracted likewise. Similarly, one reviewer (NSM) will 
check the other’s (TZ) work with a sample of the studies 
(more than 10%).
Study assessment and data mapping
For the systematic maps, no assessments or analyses will 
be considered.
For a specific health effect, a systematic map will 
present evidence assessed from epidemiological, human 
exposure, animal and ex vivo/in vitro studies separately. 
A table will be prepared for narratively mapping the 
extracted data. We will also present the result by a display 
in Tableau Public (https:// public. tableau. com/ en- us/ 
s/). An interactive map contains the above- mentioned 
information in the table will be easily and freely accessed 
online.47
Synthesis of results
We plan to develop systematic maps for each health effect 
identified via the umbrella review that is supported by a 
high evidence level. The results of a systematic map will 
include a flow chart recording the process of study selec-
tion, a table presenting the general information and the 
online display. Regarding a determined ozone- related 
health effect, we will discuss the available evidence, 
current paucity and future suggestions.
PILOT STUDY
Information retrieval for the umbrella review
We conducted a preliminary search for the umbrella 
review. Our search strategy yielded 1867 hits on 31 May 
2019. After deduplication and a primary screening, this 
number was reduced to 100 (figure 1).
Search string of a systematic map on COPD
We conducted a presearch for the systematic map 
on COPD in PubMed with the string “(ozone[tiab] 
Figure 1 Flow chart illustrating the preliminary literature search and first- step study selection of systematic reviews on ozone 
exposure and health outcome (published prior to 31 May 2019).
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OR O3[tiab]) AND (“chronic obstructive pulmonary 
disease”[tiab] OR COPD[tiab])” on 22 September 2019. 
There were 254 hits.
ETHICS AND DISSEMINATION
Since this study will only collect and analyse data from 
published and accessible studies, approval from an ethics 
committee is not required.
The umbrella review and systematic maps will be dissem-
inated in reports and peer- reviewed journals, and if appli-
cable, will also be presented at relevant conferences. The 
data of systematic maps would be publicly available at the 
website of HAWC and Tableau Public.
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